Fig. 6: Schematic representation of in solution dynamics of SARS-CoV-2 C145S Mpro tetrameric form (sample 2) analyzed with SEC-MALS.
From: An in-solution snapshot of SARS-COV-2 main protease maturation process and inhibition
a Control reaction containing tetramers at 0 h (top), after 24 h incubation (middle) and after 48 h (bottom). b Tetramers conversion reaction in presence of non-covalent inhibitor MAT-POS-e194df51-1 at 0 h (top), after 24 h incubation (middle) and after 48 h (bottom). c Tetramers conversion reaction in presence of covalent inhibitor Nirmatrelvir at 0 h (top), after 24 h incubation (middle) and after 48 h (bottom).
